Supernus Pharmaceuticals Net Income 2012-2026 | SUPN
Supernus Pharmaceuticals net income from 2012 to 2026. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
|
Supernus Pharmaceuticals Annual Net Income (Millions of US $) |
|
|---|---|
| 2025 | $-39 |
| 2024 | $74 |
| 2023 | $1 |
| 2022 | $64 |
| 2021 | $53 |
| 2020 | $127 |
| 2019 | $113 |
| 2018 | $111 |
| 2017 | $57 |
| 2016 | $91 |
| 2015 | $14 |
| 2014 | $-11 |
| 2013 | $-92 |
| 2012 | $-47 |
| 2011 | $50 |
|
Supernus Pharmaceuticals Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2026-06-30 | $-58 |
| 2026-03-31 | $-2 |
| 2025-12-31 | $-4 |
| 2025-09-30 | $-45 |
| 2025-06-30 | $22 |
| 2025-03-31 | $-12 |
| 2024-12-31 | $15 |
| 2024-09-30 | $38 |
| 2024-06-30 | $20 |
| 2024-03-31 | $0 |
| 2023-12-31 | $1 |
| 2023-09-30 | $-16 |
| 2023-06-30 | $-1 |
| 2023-03-31 | $17 |
| 2022-12-31 | $29 |
| 2022-09-30 | $2 |
| 2022-06-30 | $8 |
| 2022-03-31 | $26 |
| 2021-12-31 | $2 |
| 2021-09-30 | $22 |
| 2021-06-30 | $24 |
| 2021-03-31 | $6 |
| 2020-12-31 | $31 |
| 2020-09-30 | $40 |
| 2020-06-30 | $35 |
| 2020-03-31 | $22 |
| 2019-12-31 | $33 |
| 2019-09-30 | $29 |
| 2019-06-30 | $33 |
| 2019-03-31 | $18 |
| 2018-12-31 | $26 |
| 2018-09-30 | $28 |
| 2018-06-30 | $31 |
| 2018-03-31 | $26 |
| 2017-12-31 | $14 |
| 2017-09-30 | $16 |
| 2017-06-30 | $17 |
| 2017-03-31 | $10 |
| 2016-12-31 | $14 |
| 2016-09-30 | $62 |
| 2016-06-30 | $10 |
| 2016-03-31 | $5 |
| 2015-12-31 | $7 |
| 2015-09-30 | $4 |
| 2015-06-30 | $2 |
| 2015-03-31 | $1 |
| 2014-12-31 | $4 |
| 2014-09-30 | $-2 |
| 2014-06-30 | $3 |
| 2014-03-31 | $-16 |
| 2013-12-31 | $-22 |
| 2013-09-30 | $-24 |
| 2013-06-30 | $-27 |
| 2013-03-31 | $-18 |
| 2012-12-31 | $-14 |
| 2012-09-30 | $-13 |
| 2012-06-30 | $-10 |
| 2012-03-31 | $-10 |
| 2011-12-31 | $82 |
| 2011-09-30 | $-11 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.409B | $0.719B |
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |